Which drug to use for the initiation of treatment for early Parkinson's disease
Marttila, R.
Duodecim; Laaketieteellinen Aikakauskirja 120(5): 587-590
2004
ISSN/ISBN: 0012-7183 PMID: 15060995 Document Number: 567362
Document emailed within 1 workday
Related Documents
Dickerson, L.M.; Young, S.E.; Simpson, W.M.; Nashelsky, J. 2005: Treatment of early Parkinson's disease American Family Physician 72(3): 497-500Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Stacy, M.; Brownlee, H.J. 1996: Treatment options for early Parkinson's disease American Family Physician 53(4): 1281-1287
Báez Feliciano, D.V.; Gómez, M.ía.A.; Fernández-Santos, D.M.; Quintana, R.; Rios-Olivares, E.; Hunter-Mellado, R.F. 2008: Profile of Puerto Rican HIV/AIDS patients with early and non-early initiation of injection drug use Ethnicity and Disease 18(2 Suppl 2: S2
Bhat, V.; Weiner, W.J. 2005: Parkinson's disease. Diagnosis and the initiation of therapy Minerva Medica 96(3): 145-154
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41
Greene, P.; Cote, L.; Fahn, S. 1993: Treatment of drug-induced psychosis in Parkinson's disease with clozapine Advances in Neurology 60: 703-706
Friedman, A. 1985: Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies Neurologia i Neurochirurgia Polska 19(5): 401-403
Montgomery, E.B.; Gorman, D.S.; Nuessen, J. 1991: Motor initiation versus execution in normal and Parkinson's disease subjects Neurology 41(9): 1469-1475
Goulley, F.; Wolmark, Y.; Bourdeix, I.; Chaumet-Riffaud, P.D. 1993: Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms Therapie 48(3): 233-238
Wang, H.; Brown, K.S.; Wang, G.; Ding, G.; Zang, C.; Wang, J.; Reilly, K.H.; Chen, H.; Wang, N. 2011: Knowledge of HIV seropositivity is a predictor for initiation of illicit drug use: incidence of drug use initiation among female sex workers in a high HIV-prevalence area of China Drug and Alcohol Dependence 117(2-3): 226-232
Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Aaltonen, H.; Kilkku, O.; Heinonen, E.; Mäki-Ikola, O. 1998: Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality Bmj 317(7172): 1586-1587
Katunina, E.A.; Titova, N.V.; Avakian, G.N. 2010: Methods of diagnosis early stage Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 110(12): 112-118
Csanda, E.; Tárczy, M. 1987: Selegiline in the early and late phases of Parkinson's disease Journal of Neural Transmission. Supplementum 25: 105-113
Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Factor, S.A.; Molho, E.S.; Podskalny, G.D.; Brown, D. 1995: Parkinson's disease: drug-induced psychiatric states Advances in Neurology 65: 115-138
Gehlen, W. 1980: Adverse effects of drug therapy in Parkinson disease Medizinische Monatsschrift für Pharmazeuten 3(4): 104-110
Chen, X.; Gumina, G.; Virga, K.G. 2019: Recent Advances in Drug Repurposing for Parkinson's Disease Current Medicinal Chemistry 26(28): 5340-5362